術前化学療法
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.Mamounas EP, Bandos H, White JR, et al. N Engl J Med. 2025 Jun 5;392(21):2113-2124. DOI: 10.1056/NEJMoa2414859. PMID: 40466065; PMCID: PMC12269788. 【背景】・乳…
Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma: An Academic Gastrointestinal Cancer Consortium (AGICC) Study.Cohen DJ, Goldberg JD, Leichman L, et al. Oncologist. 2025 Sep 16:oyaf271. doi: 10.1093/…
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Janssen QP, van Dam JL, van Bekkum M…
Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study.Chen J, Miao C, Wang X, et al. BMC Cancer. 2025 Aug 5;25(…
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Y…
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. Deng Y, Chi P, Lan P, et al. J Clin Oncol. 2019 Dec 1;37(34):3223-3233…
Neoadjuvant chemotherapy versus long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of 5,168 cases.Zhou W, Wang X, Dan J, et al. Front Oncol. 2025 Jun 26;15:1542885. DOI: 10.3…
